chronic kidney disease market sizekidney disease marketAcross the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — the was valued at approximately USD 5 billion in 2025 and is projected to keep expanding through 2036. Today's landscape is built on erythropoietin stimulating agents, ACE inhibitors, ARBs, antidiabetic drugs, secondary hyperparathyroidism treatments, and urate-lowering therapies, with SGLT2 inhibitors and non-steroidal MRAs now emerging as the dominant growth segments within the broader .

Chronic Kidney Disease Epidemiology

chronic kidney disease epidemiology forecast Patient burden data underpin every forecast in this space. In 2025, the 7MM housed roughly 82.5 million people living with the disease, of whom nearly 14.5 million had received a formal diagnosis. The US carried the single largest diagnosed population, at around 3.8 million cases, or roughly a quarter of the 7MM total. Stage III was the most common severity level among US patients, and hyperparathyroidism was the leading complication, ahead of anemia and metabolic acidosis. Diagnosed cases also skewed toward women, and continued growth in the geriatric population, combined with wider eGFR and albuminuria screening, is expected to keep pushing the upward through 2036.

Current Chronic Kidney Disease Treatment Landscape

chronic renal failure marketCare generally follows a stepwise, additive model. RAS blockade and lifestyle intervention come first, followed by SGLT2 inhibitors such as empagliflozin (JARDIANCE) and dapagliflozin (FARXIGA/FORXIGA), which now serve as background therapy across most disease types. Where diabetes-related disease and residual albuminuria persist, the non-steroidal MRA finerenone (KERENDIA) is frequently added to further lower cardiorenal risk. This layering of therapies rather than reliance on a single agent is what continues to reshape the .

Key Factors Driving the Chronic Kidney Disease Market

CKD marketGrowth is being driven by three main forces. Expanded screening among diabetic, hypertensive, and cardiovascular patients is identifying more cases earlier, feeding a larger treated population. At the same time, combination cardiorenal regimens — pairing SGLT2 inhibitors with non-steroidal MRAs and, increasingly, aldosterone synthase inhibitors — are becoming the standard rather than the exception, and this shift is considered the single biggest revenue contributor in the space. A broadening late-stage pipeline covering endothelin receptor antagonism, aldosterone synthase inhibition, APOL1 inhibition, and cell-based therapy is adding further competitive depth to the .

Chronic Kidney Disease Drug Analysis & Competitive Landscape

chronic kidney disease drugs marketSeveral late-stage assets illustrate where the next wave of growth may come from. AstraZeneca's zibotentan/dapagliflozin combination progressed into Phase III proteinuria trials after strong Phase IIb results. Boehringer Ingelheim's vicadrostat-plus-empagliflozin regimen has already demonstrated notable albuminuria reduction in earlier testing. ProKidney's cell therapy candidate rilparencel and Mineralys Therapeutics' lorundrostat remain in active late-stage development, while Maze Therapeutics' MZE829 recently delivered the first clinical proof-of-concept in APOL1-mediated kidney disease — developments that are steadily diversifying the beyond its traditional glycemic- and blood-pressure-centered approach.

Chronic Kidney Disease Unmet Needs

renal failure treatment marketEven with this progress, meaningful gaps remain. Existing treatments slow disease progression but do not halt or reverse it, and because early-stage disease tends to be silent, many patients are only diagnosed once considerable kidney damage has already occurred. Cardiorenal risk also persists even under combination SGLT2 inhibitor and MRA therapy, and precision options for genetically driven forms of disease, such as APOL1-mediated kidney disease, remain limited — a gap that continues to define opportunity within the .

Chronic Kidney Disease Market Outlook

chronic kidney disease treatment marketend stage renal disease marketLooking forward, SGLT2 inhibitors and finerenone are expected to remain the volume backbone of therapy, while endothelin- and aldosterone-pathway combinations are set to drive the next phase of add-on growth, contingent on outcomes and safety data around fluid retention and hyperkalemia. Rilparencel and MZE829 could achieve premium positioning in advanced and genetically defined disease if pivotal trials succeed, and anemia-targeted candidates such as DISC-0974 may open a largely uncontested new revenue segment. Regionally, the US holds the largest share, followed by Germany and the UK in Europe, while Japan contributes a sizeable double-digit portion of the 7MM total. As diagnosis rates climb and the late-stage pipeline matures, adjacent segments — including the and the — are also poised to expand through 2036.

Latest Reports Offered by Delveinsight

gene therapy in cns disorder market hepatic encephalopathy market obesity market rett syndrome market schizophrenia market trigeminal neuralgia market size aarskog scott syndrome market acne vulgaris market acrocallosal syndrome market acute pancreatitis market amyloidosis market antibody mediated rejection market aplastic anemia market arteriovenous malformations market attention deficit hyperactivity disorder adhd market atypical teratoid rhabdoid tumors market bcl-2 inhibitors market beta thalassemia market bone densitometers market brain/cranial implants market c-met non-small cell lung cancer market cancer cachexia market castration-resistant prostate cancer market cataract market | | | | | | | | | | | | | | | | | | | | | | | |

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

The Changing Chronic Kidney Disease Market: Drug Innovation, Pipeline Progress, and Future Outlook

Across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — the chronic kidney disease market size was valued at app